For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Research and development | 1,696,718 | 1,682,550 | ||
| General and administrative | 1,729,935 | 1,974,859 | ||
| Total expenses | 3,426,653 | 3,657,409 | ||
| Loss from operations | -3,426,653 | -3,657,409 | ||
| Interest income | 126,316 | 318,208 | ||
| Net loss | -3,300,337 | -3,339,201 | ||
| Basic EPS | -0.02 | -0.02 | ||
| Diluted EPS | -0.02 | -0.02 | ||
| Basic Average Shares | 172,511,901 | 172,262,889 | ||
| Diluted Average Shares | 172,511,901 | 172,262,889 | ||
Inhibitor Therapeutics, Inc. (INTI)
Inhibitor Therapeutics, Inc. (INTI)